Perinatal HIV: Progress, Gaps, and the Next Clinical Priorities

Perinatal HIV prevention has changed dramatically since the early years of the epidemic. Effective antiretroviral therapy, safer delivery practices, infant prophylaxis, and evidence-based feeding guidance have made transmission from mother to child largely preventable when families can access timely, continuous care. In many countries, infants born to women living with HIV now have an excellent chance of remaining HIV-free.

These achievements are substantial, but they are unevenly distributed. New infections still occur when diagnosis is delayed, treatment is interrupted, viral load is not monitored, or newborn follow-up ends too soon. Structural barriers such as stigma, poverty, conflict, distance from health facilities, and shortages of trained personnel can turn a proven intervention into an unavailable one.

The scientific and clinical community has long used international meetings to compare strategies across regions. The FAOPS 2020 congress site reflects the wider interest in perinatal and neonatal medicine, including research, clinical practice, and cooperation across Asia and Oceania. Although that Tokyo meeting was canceled during the COVID-19 pandemic, its central concerns remain urgent: protecting pregnant patients, newborns, and families while strengthening the systems that deliver care.

How Prevention Has Transformed Maternal And Infant Care

The most important advance has been the move from short-term prevention to lifelong HIV treatment. Antiretroviral therapy suppresses the mother’s viral load, improves her health, and sharply reduces the likelihood of HIV transmission during pregnancy and childbirth. When viral suppression is sustained, the risk can fall to very low levels. Treatment also protects future pregnancies and reduces the possibility of sexual transmission to partners.

Prevention now begins with routine, voluntary HIV testing during antenatal care, followed by rapid linkage to treatment. Repeat testing may be valuable later in pregnancy or during breastfeeding when a person has ongoing exposure risk. Combination therapy, adherence support, viral-load measurement, and coordinated obstetric and infectious-disease services form a connected prevention pathway rather than isolated interventions.

Infant prophylaxis has also evolved. Newborns with higher exposure risk may require intensified antiretroviral regimens, while those with lower risk can receive an appropriate preventive course based on national or international guidance. Early infant diagnosis using virologic testing allows clinicians to identify infection before symptoms develop. These interventions work best when every handoff—from maternity ward to laboratory to pediatric clinic—is reliable.

Treatment During Pregnancy And Breastfeeding

Pregnancy requires careful integration of HIV care with routine maternal health services. Clinicians must select antiretroviral combinations that are effective against the patient’s virus, compatible with pregnancy, and practical to continue after delivery. Drug interactions, renal or hepatic disease, tuberculosis treatment, and previous treatment failure can complicate decisions, making specialist consultation important when available.

Viral-load results near delivery help guide intrapartum planning. In some settings, a low viral load supports vaginal birth when there are no obstetric contraindications, while a high or unknown viral load may require additional measures. Cesarean delivery is not a universal solution; its value depends on viral suppression, local protocols, obstetric indications, and the safety of surgery. Avoiding unnecessary invasive procedures can also reduce opportunities for blood exposure.

Breastfeeding guidance must reflect the setting rather than rely on a single global rule. Where safe, sustainable replacement feeding is available, avoiding breastfeeding eliminates postnatal transmission through breast milk. In many regions, however, breastfeeding with effective maternal therapy is recommended because unsafe water, inadequate nutrition, and infectious disease may create greater risks. Families need clear counseling, reliable medicines, and follow-up that continues throughout the breastfeeding period.

Where The Care Pathway Can Break Down

The biology of transmission is only part of the problem. A woman may test negative early in pregnancy and acquire HIV later, or she may know her status but face barriers to starting or continuing treatment. Late presentation for antenatal care, limited confidentiality, partner violence, fear of disclosure, and judgmental treatment can all affect engagement with services.

Infant diagnosis presents its own operational challenges. Virologic tests may depend on distant laboratories, transport networks, electricity, skilled technicians, and systems for returning results. Point-of-care testing can shorten the time to diagnosis, but it requires quality assurance, maintenance, supply management, and a clear response when a result is positive. A test that produces no action is an incomplete intervention.

Retention after delivery is another persistent weakness. Mothers may prioritize the newborn’s appointments while neglecting their own care, or they may stop attending once the immediate pregnancy-related support ends. Pediatric follow-up must include repeat testing when indicated, prophylaxis review, growth monitoring, immunization, feeding support, and rapid initiation of treatment for any infant who tests positive. Family-centered services are more effective than separating maternal and infant care into disconnected programs.

The table below summarizes how established interventions contribute to prevention and where implementation still requires attention.

Equity, Stigma, And Health-System Resilience

Perinatal HIV outcomes often reflect social conditions as much as clinical quality. Adolescents, migrants, refugees, Indigenous communities, and people living in remote areas may encounter additional barriers to testing and treatment. Women who fear disclosure may avoid carrying medication or attending a clinic close to home. Services that ignore these realities can unintentionally increase risk.

Respectful care is a clinical intervention. Confidential counseling, informed consent, interpreters, peer navigators, and non-discriminatory maternity services help patients remain connected to treatment. Involving partners and families can be beneficial when the patient wants that support, but confidentiality and personal safety must remain central. Coercive testing or disclosure can damage trust and drive people away from care.

Health systems also need resilience during emergencies. The COVID-19 pandemic showed how quickly travel restrictions, clinic closures, staff redeployment, and supply-chain disruptions can affect chronic disease management and maternal services. Multi-month dispensing, community medicine distribution, telehealth where feasible, flexible appointment systems, and integrated HIV and primary-care platforms can reduce the effects of disruption without weakening clinical oversight.

Research Priorities For The Next Phase

Research should continue to improve prevention while addressing questions that affect daily clinical decisions. Long-acting antiretroviral technologies may reduce the burden of daily medication, but their use during pregnancy and breastfeeding requires robust safety data, clear dosing strategies, and systems capable of managing injections or other delivery methods. New formulations should be evaluated in the populations most affected by perinatal HIV, not only in easier-to-reach groups.

Studies are also needed on HIV acquisition during pregnancy and breastfeeding, when infection may be recent and viral levels can be high. Prevention options such as pre-exposure prophylaxis may benefit people with ongoing risk, but counseling, testing, adherence support, and access must be designed around pregnancy and postpartum realities. Research should include maternal preferences, partner dynamics, mental health, and the practical costs of care.

Implementation science can close the distance between guidelines and outcomes. Useful questions include which models best retain families after delivery, how point-of-care diagnosis affects treatment initiation, and how community health workers can support adherence without compromising privacy. Regional collaboration is especially valuable because health systems across Asia and Oceania differ in resources, epidemic patterns, language, and cultural expectations.

Clinical Priorities That Strengthen Prevention

Every maternity and newborn service can use a small set of practical priorities to improve continuity and reduce missed opportunities:

• Offer voluntary HIV testing early in pregnancy, with repeat testing when clinically or epidemiologically appropriate.
• Start or continue effective antiretroviral therapy promptly and provide adherence support that addresses transport, stigma, cost, and disclosure concerns.
• Use viral-load results to guide risk assessment, delivery planning, infant prophylaxis, and postpartum care.
• Create a documented pathway for newborn testing, result delivery, prophylaxis review, and rapid treatment initiation when required.
• Link maternal HIV care, pediatric services, contraception, mental health support, and primary care beyond the first postpartum visit.

These actions depend on dependable supplies, trained staff, accurate records, and communication between facilities. Measuring performance should include more than the number of tests performed. Programs should track treatment initiation, viral suppression near delivery, infant testing completion, time to result return, retention through breastfeeding, and patient-reported experience of care.

Communities should help shape those measurements. Women living with HIV, peer supporters, advocates, and local health workers understand barriers that may be invisible in hospital data. Their participation can improve counseling materials, appointment systems, service hours, and approaches to confidentiality. Ethical research and service design should treat families as partners with expertise, not simply as recipients of interventions.

Perinatal HIV prevention has demonstrated what coordinated science and public health can achieve. The next gains will come from applying that evidence consistently, protecting dignity, and investing in the points where care is most likely to fail. Clinicians, researchers, health administrators, and community organizations can act now by strengthening testing, treatment continuity, infant diagnosis, and postpartum support so that every pregnancy has access to a dependable path toward an HIV-free start to life.